Healing & Repair
VIP (Vasoactive Intestinal Peptide)
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Immunity Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10 mg
Dosing window: Morning or early afternoon
Receptor / target: VIP Receptors
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 50mcg - 100mcg daily | Administered very slowly; monitor blood pressure closely. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: 8-Week Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100mcg 1x/day, 5 days/week | Dose in the morning or early afternoon to align with VIP's natural role in regulating circadian rhythms, energy levels, and cellular function. |
| Week 2-3 | 150mcg 1x/day, 5 days/week | |
| Weeks 4-8 | 200mcg 1x/day, 5 days/week |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: 3-Month Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 200mcg 1x/day, 5 days/week | Dose in the morning or early afternoon to align with VIP's natural role in regulating circadian rhythms, energy levels, and cellular function. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (VIP Receptors); route Subcutaneous; timing Morning or early afternoon. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Hypotension (low blood pressure): VIP is one of the most potent endogenous vasodilators; administering it in a subject with baseline low blood pressure risks dangerous acute hypotension, syncope, and cardiovascular instability. Limited / unverified
- Use before upstream CIRS inflammatory markers are normalized: per the Shoemaker Protocol, VIP is the final intervention step; using VIP in subjects with unresolved elevated MMP-9, TGF-β1, or C4a will produce insufficient therapeutic benefit and may worsen symptoms. Limited / unverified
- Active ongoing mold or biotoxin exposure: VIP will not maintain therapeutic effect if the biotoxin source has not been eliminated (e.g., still living in a water-damaged building). Limited / unverified
- Hypersensitivity to VIP or peptide excipients. Limited / unverified
- Concurrent use of other vasodilatory agents (e.g., PDE5 inhibitors, nitrates, alpha-blockers): additive vasodilation and hypotension risk. Limited / unverified
- Subjects on antihypertensive medications: the combined vasodilatory effect may reduce blood pressure below safe thresholds. Limited / unverified
- VIPoma (VIP-secreting tumor): endogenous VIP is already pathologically elevated; exogenous administration is absolutely contraindicated. Limited / unverified
- Severe cardiovascular disease with labile blood pressure or recent myocardial infarction. Limited / unverified
- Pregnancy: VIP plays a role in uterine tone regulation; exogenous VIP administration during pregnancy is not established as safe. Limited / unverified
- Pediatric use: safety not established. Limited / unverified
Side effects (limited evidence)
- Rapid blood pressure drop (hypotension): the primary and most serious adverse effect; VIP-mediated smooth muscle relaxation in systemic and pulmonary vasculature can produce a sudden, significant blood pressure decrease within minutes of injection, particularly if administered quickly; the protocol instruction to inject "very slowly" is the critical mitigating intervention. Limited / unverified
- Dizziness and lightheadedness: secondary to acute vasodilation and blood pressure drop; patients should be seated or supine during administration. Limited / unverified
- Flushing and sensation of warmth: vasodilation-mediated; particularly facial flushing; onset within minutes; typically transient. Limited / unverified
- Rapid heartbeat (tachycardia): reflex compensatory heart rate increase in response to vasodilation-induced blood pressure drop; transient. Limited / unverified
- Headache: vasodilation-related; common in subjects sensitive to vasodilatory peptides. Limited / unverified
- Nausea: gastrointestinal smooth muscle relaxation; VIP is an intestinal secretagogue; dose-related. Limited / unverified
- Diarrhea and watery stools: VIP stimulates intestinal chloride secretion and fluid secretion in the gut; at higher doses, this is a pharmacological consequence of the mechanism (VIPoma syndrome, characterized by profuse watery diarrhea, is the extreme pathological version of this effect). Limited / unverified
- Transient nasal congestion: more commonly associated with intranasal route; mild. Limited / unverified
- Increased susceptibility to intracellular pathogens (theoretical): VIP's immunomodulatory tolerance programming that promotes T-regulatory cells and suppresses Th1 responses could, at sustained high doses, impair cell-mediated immunity against intracellular pathogens (mycobacteria, Listeria, viruses). Limited / unverified
- Syncope: in subjects with baseline hypotension or cardiovascular instability; the most serious acute risk; requires lying down, fluid intake, and monitoring. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.